Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Phase I/II Study of the Safety of Subcutaneous Interferon Gamma-1b Combined With Rituximab in Patients With Low Grade/Follicular Non-Hodgkin's Lymphoma

Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)

International study with sites in the Czech Republic and Poland

• Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab therapy
• Patients who were on other therapy including CHOP or radiation
• Previous therapy must have concluded 30 days prior to enrollment
• Demonstrable CD20-positive tumor population in lymph nodes or bone marrow